Carlos Alberto Valdes, Griffin Stinson, Omar M Sharaf, Fabian Jimenez Contreras, Ahmet Bilgili, Mustafa M Ahmed, Juan Vilaro, Alex M Parker, Mohammad A Z Al-Ani, Daniel Demos, Juan Aranda, Mark Bleiweis, Thomas M Beaver, Eric I Jeng
OBJECTIVE: Impella 5.5 (Abiomed, Danvers, MA, USA) is approved by the US Food and Drug Administration (FDA) for mechanical circulatory support for ≤14 days. It is unknown whether prolonged support is associated with worse outcomes. We sought to review our single-center experience with Impella 5.5 and compare outcomes based on support duration. METHODS: We retrospectively reviewed adult patients (≥18 years old) supported with Impella 5.5 at our institution (May 2020 to April 2023)...
November 27, 2023: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery